This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Waters (WAT) Q2 Earnings & Sales Beat Estimates, Fall Y/Y
by Zacks Equity Research
Waters' (WAT) second-quarter results are hurt by weak end-market momentum and softness in Asia, Americas and Europe.
Philips (PHG) Q2 Earnings Rise, Revenues Fall Year Over Year
by Zacks Equity Research
Philips' (PHG) second-quarter results benefit from strong momentum across the Diagnosis & Treatment, Connected Care and Personal Health businesses.
AMED vs. USPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMED vs. USPH: Which Stock Is the Better Value Option?
Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Down
by Zacks Equity Research
Amedisys (AMED) delivers year-over-year growth in all three of its segmental revenues in the second quarter of 2024.
Compared to Estimates, Amedisys (AMED) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Amedisys (AMED) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Amedisys (AMED) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 8.20% and 2.05%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why Amedisys (AMED) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AMED or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMED vs. USPH: Which Stock Is the Better Value Option?
Encompass Health (EHC), Piedmont Expand Ties to Serve Georgia
by Zacks Equity Research
Encompass Health (EHC) expands its partnership with Piedmont to better serve Georgians with the Walton Rehabilitation Hospital.
AMED vs. USPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMED vs. USPH: Which Stock Is the Better Value Option?
Here's Why Amedisys (AMED) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
AMED vs. USPH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMED vs. USPH: Which Stock Is the Better Value Option?
UnitedHealth (UNH), Amedisys Clear Merger Hurdle With Asset Sale
by Zacks Equity Research
By selling these assets, UnitedHealth (UNH) and Amedisys aim to avoid potential monopoly issues and ensure a smoother merger process.
Why Amedisys (AMED) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Amedisys (AMED) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Is Amedisys (AMED) Up 5.5% Since Last Earnings Report?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amedisys (AMED) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Amedisys (AMED) tops on revenue and earnings estimates in the first quarter of fiscal 2024.
Compared to Estimates, Amedisys (AMED) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Amedisys (AMED) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Amedisys (AMED) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 1.98% and 1.21%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Premium Growth Propels Humana (HUM) to Easy Q1 Earnings Beat
by Zacks Equity Research
Humana (HUM) bumps up individual Medicare Advantage membership growth guidance.
Amedisys (AMED) Earnings Expected to Grow: What to Know Ahead of Q1 Release
by Zacks Equity Research
Amedisys (AMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Amedisys (AMED) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Should You Buy HCA Healthcare (HCA) Ahead of Q1 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) first-quarter results are likely to reflect increased admissions and patient days.